M Walsh

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. pmc Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis
    Michael Walsh
    Addenbrooke s Hospital, Cambridge, UK
    Arthritis Care Res (Hoboken) 62:1166-73. 2010
  2. pmc Association between routine and standardized blood pressure measurements and left ventricular hypertrophy among patients on hemodialysis
    Jaspreet Khangura
    Department of Medicine, University of British Columbia, Vancouver, Canada
    BMC Nephrol 11:13. 2010
  3. pmc Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis
    Michael Walsh
    McMaster University, Hamilton, Ontario, Canada
    Arthritis Care Res (Hoboken) 63:1055-61. 2011
  4. ncbi request reprint Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)
    M Walsh
    Vasculitis Clinic, Box 118, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Ann Rheum Dis 67:1322-7. 2008
  5. doi request reprint Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis
    M Walsh
    Department of Medicine, University of Calgary, Calgary, AB, Canada
    Lupus 19:628-33. 2010
  6. ncbi request reprint Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis
    Michael Walsh
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Clin J Am Soc Nephrol 2:968-75. 2007
  7. doi request reprint Targeting the B cell in vasculitis
    Michael Walsh
    Vasculitis Clinic, Addenbrooke s Hospital, Hills Road, Box 118, Cambridge, CB2 2QQ, UK
    Pediatr Nephrol 24:1267-75. 2009
  8. ncbi request reprint Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis
    Michael Walsh
    Vasculitis and Lupus Clinic, Department of Renal Medicine, Addenbrooke s Hospital, Cambridge, UK
    J Nephrol 20:119-29. 2007
  9. pmc Histopathologic features aid in predicting risk for progression of IgA nephropathy
    Michael Walsh
    Division of Nephrology, Foothills Medical Centre, Calgary, AB, T2N 0L9, Canada
    Clin J Am Soc Nephrol 5:425-30. 2010
  10. ncbi request reprint Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future
    M Walsh
    Department of Renal Medicine, Addenbrooke s Hospital, Cambridge, United Kingdom
    Kidney Int 72:676-82. 2007

Collaborators

Detail Information

Publications21

  1. pmc Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis
    Michael Walsh
    Addenbrooke s Hospital, Cambridge, UK
    Arthritis Care Res (Hoboken) 62:1166-73. 2010
    ..The role of low-dose glucocorticoids (GC) in relapse prevention is controversial. We undertook a systematic review and meta-analysis to determine if GC target doses influence relapses of AAV...
  2. pmc Association between routine and standardized blood pressure measurements and left ventricular hypertrophy among patients on hemodialysis
    Jaspreet Khangura
    Department of Medicine, University of British Columbia, Vancouver, Canada
    BMC Nephrol 11:13. 2010
    ..We sought to determine agreement between various blood pressure measurement methods, as well as identify which method was the strongest correlate of LV hypertrophy among patients on hemodialysis...
  3. pmc Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis
    Michael Walsh
    McMaster University, Hamilton, Ontario, Canada
    Arthritis Care Res (Hoboken) 63:1055-61. 2011
    ..Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) can present with a broad spectrum of signs and symptoms. The relative effects of different manifestations on health-related quality of life (HRQOL) are unknown...
  4. ncbi request reprint Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)
    M Walsh
    Vasculitis Clinic, Box 118, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    Ann Rheum Dis 67:1322-7. 2008
    ..Humanised monoclonal anti-CD52 antibodies (alemtuzumab, CAMPATH-1H) selectively deplete lymphocytes. We present long-term follow-up results of patients with relapsing/refractory AASV treated with CAMPATH-1H...
  5. doi request reprint Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis
    M Walsh
    Department of Medicine, University of Calgary, Calgary, AB, Canada
    Lupus 19:628-33. 2010
    ..This variability likely represents clinical equipoise. A randomized trial evaluating the effect of glucocorticoid use after induction of response is warranted...
  6. ncbi request reprint Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis
    Michael Walsh
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Clin J Am Soc Nephrol 2:968-75. 2007
    ..A systematic review and meta-analysis were performed to determine the risk for failure to induce remission of lupus nephritis in patients who were treated with mycophenolate mofetil compared with cyclophosphamide...
  7. doi request reprint Targeting the B cell in vasculitis
    Michael Walsh
    Vasculitis Clinic, Addenbrooke s Hospital, Hills Road, Box 118, Cambridge, CB2 2QQ, UK
    Pediatr Nephrol 24:1267-75. 2009
    ..Several other B-cell-directed therapies are in development and may offer rational alternatives or adjunctives to traditional treatments...
  8. ncbi request reprint Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis
    Michael Walsh
    Vasculitis and Lupus Clinic, Department of Renal Medicine, Addenbrooke s Hospital, Cambridge, UK
    J Nephrol 20:119-29. 2007
  9. pmc Histopathologic features aid in predicting risk for progression of IgA nephropathy
    Michael Walsh
    Division of Nephrology, Foothills Medical Centre, Calgary, AB, T2N 0L9, Canada
    Clin J Am Soc Nephrol 5:425-30. 2010
    ..Accurately identifying patients who are at risk for progressive disease is challenging. The extent to which histopathologic features improves prognostication is uncertain...
  10. ncbi request reprint Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future
    M Walsh
    Department of Renal Medicine, Addenbrooke s Hospital, Cambridge, United Kingdom
    Kidney Int 72:676-82. 2007
    ..Future randomized control trials and long-term follow-up studies are required to confirm the role of RTX and other B-cell targeting therapies in AASV and SLE...
  11. doi request reprint Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
    Rachel B Jones
    Vasculitis and Lupus Clinic, Renal Unit, Addenbrooke s Hospital, Cambridge, United Kingdom
    N Engl J Med 363:211-20. 2010
    ..Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens...
  12. ncbi request reprint What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?
    Rachel B Jones
    Renal Unit, Vasculitis and Lupus Clinic, Box 118, Addenbrooke s Hospital, Hills Road, Cambridge CB2 OQQ, UK
    Curr Opin Rheumatol 21:256-61. 2009
    ..The precise role of MMF is under ongoing evaluation. This review provides an up-to-date summary of MMF and its use as remission induction and maintenance therapy for lupus nephritis...
  13. doi request reprint Health-related quality of life in a cohort of adult patients with mild hemophilia A
    M Walsh
    The Clinical Epidemiology Unit, Department of Medicine, Memorial University of Newfoundland, St John s, NL, Canada
    J Thromb Haemost 6:755-61. 2008
    ..To compare the health-related quality of life among adult males affected with mild hemophilia A due to the same mutation (Val2016ala) to that of unaffected age and sex matched controls from the same general population...
  14. ncbi request reprint Association between multidisciplinary care and survival for elderly patients with chronic kidney disease
    Brenda R Hemmelgarn
    Department of Medicine, Community Health Schiences, University of Calgary, Calgary, Canada
    J Am Soc Nephrol 18:993-9. 2007
    ..The benefits of MDC and an assessment of their economic impact should be tested in a randomized, controlled trial...
  15. doi request reprint Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis
    Vinay Deved
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Am J Kidney Dis 54:1089-97. 2009
    ..Ascorbic acid is believed to improve anemia in patients with end-stage renal disease, but its overall effectiveness is unclear...
  16. doi request reprint The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial
    Michael Walsh
    Department of Medicine, University of Calgary, Alberta, Canada
    Hemodial Int 14:174-81. 2010
    ..The effects of NHD on PTH are variable. The impact of these changes on long-term cardiovascular and bone-related outcomes requires further investigation...
  17. ncbi request reprint Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial
    Bruce F Culleton
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    JAMA 298:1291-9. 2007
    ..Morbidity and mortality rates in hemodialysis patients remain excessive. Alterations in the delivery of dialysis may lead to improved patient outcomes...
  18. pmc The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: rationale and study design of a randomized controlled pilot study
    Michael Walsh
    Department of Medicine, University of Calgary, Calgary, Canada
    BMC Nephrol 7:2. 2006
    ..We have undertaken a multi-center RCT in hemodialysis patients comparing the effect of NHD to CvHD on left ventricular (LV) mass, as measured by cardiac magnetic resonance imaging (cMR)...
  19. ncbi request reprint A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life
    Michael Walsh
    Department of Medicine, University of Calgary, Alberta, Canada
    Kidney Int 67:1500-8. 2005
    ..A systematic review of the current available literature was undertaken to examine the effect of nocturnal hemodialysis on key health outcomes...
  20. ncbi request reprint Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications cohort
    Aklilu A Yishak
    Department of Medicine, University of Pittsburgh School of Medicine, and Veterans Pittsburgh Health Care System of Pittsburgh, Pittsburgh, PA 15213, USA
    Nephrol Dial Transplant 21:93-100. 2006
    ..Predictors of diabetic nephropathy are only partly known and traditional risk factors do not adequately explain disease risk. We thus examined novel risk factors for overt nephropathy (ON) in type 1 diabetes...
  21. ncbi request reprint Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study
    Tina Costacou
    Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    J Diabetes Complications 19:183-93. 2005
    ..13, 95% Cl=1.03-1.24; HRs are per standard deviation increase) but not hard CAD. Study results suggest that E-selectin may enhance CAD prediction beyond traditional risk factors or markers of oxidative stress in Type 1 diabetes...